Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research
Launched by CHINESE ALLIANCE AGAINST LUNG CANCER · Feb 23, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Mobile Lung Nodule Observatory trial is studying how lung nodules can cause various symptoms that may affect a person's quality of life and treatment options. Researchers want to learn more about these symptoms and their development over time. This study is currently recruiting participants who are between 18 and 90 years old, have a lung nodule smaller than 3 centimeters, and own a smartphone. Participants will need to agree to a 10-year follow-up and complete some online steps to register for the study.
If you or a family member are eligible and decide to participate, you can expect to use a smartphone app that helps track your symptoms and health over a long period. This information will contribute to a better understanding of how lung nodules can impact patients, potentially leading to improved care and treatment in the future. It’s important to note that those who have had chemotherapy for lung cancer or lung surgery are not eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 90
- • There is a chest lesion less than 3cm width (examined by Thin-Section CT)
- • The patient or his family member owns a smartphone
- • Signed informed consent
- • Completed the installation and registration of mobile terminal software online
- • Willing to complete a 10-year period of follow-up
- Exclusion Criteria:
- • Not equipped with a smartphone
- • Cannot complete the installation or registration of smartphone application software online
- • Received prior chemotherapy medications for lung cancer or received lung surgical removal treatment
About Chinese Alliance Against Lung Cancer
The Chinese Alliance Against Lung Cancer is a dedicated clinical trial sponsor focused on advancing research and treatment options for lung cancer. Comprising a coalition of leading medical institutions, researchers, and healthcare professionals, the alliance aims to enhance patient outcomes through innovative clinical trials and collaborative studies. With a commitment to scientific rigor and ethical standards, the organization seeks to bridge the gap between groundbreaking research and clinical application, fostering a multidisciplinary approach to combatting lung cancer. By prioritizing patient-centered initiatives and harnessing the latest advancements in medical science, the alliance plays a pivotal role in transforming lung cancer care in China and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Beijing, , China
Beijing, , China
Cangzhou, , China
Changsha, , China
Chaoyang, , China
Chengdu, , China
Chongqing, , China
Chongqing, , China
Dalian, , China
Guizhou, , China
Hangzhou, , China
Hangzhou, , China
Kunming, , China
Liaocheng, , China
Quanzhou, , China
Quzhou, , China
Shanghai, , China
Shanghai, , China
Shanghai, , China
Tianjin, , China
Weifang, , China
Wudang, , China
Wuhu, , China
Wuxi, , China
Xiamen, , China
Xian, , China
Yantai, , China
Zhengzhou, , China
Zhengzhou, , China
Zibo, , China
Zibo, , China
Zigong, , China
Zunyi, , China
Patients applied
Trial Officials
Chunxue Bai, M.D, Ph.D
Study Chair
Chinese Alliance Against Lung Cancer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials